Althx.Pa
ALTHX.PA operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.
Business. ALTHX.PA operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ALTHX.PA operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of medical products and services.
The company's capital structure is characterized by a negative equity position of -1,656,910 EUR and a debt-to-equity ratio of -1.73, indicating a significant reliance on debt financing. The liquidity position is moderate, with a current ratio of 1.03 and cash and equivalents amounting to 252,280 EUR. The negative net cash position after subtracting total debt highlights potential liquidity constraints.
Profitability metrics show a challenging financial performance, with a return on assets of -0.472 and a return on equity of 1.0653. These figures indicate that the company is not generating returns that cover its cost of capital, which is a concern compared to industry benchmarks. The operating and net losses of -2,526,370 EUR and -1,765,160 EUR, respectively, further underscore the company's financial difficulties.
The company's revenue concentration is not explicitly detailed in the provided data, but the absence of segment-specific revenue information suggests a lack of diversification. This could pose a risk if the company's primary revenue streams face disruptions. The geographic exposure is also not specified, making it difficult to assess regional dependencies.
The growth trajectory is uncertain, with no specific revenue growth projections provided. The company's operating and free cash flows are negative, at -3,368,770 EUR and -1,701,650 EUR, respectively, indicating ongoing cash outflows. The capital expenditure of -32,720 EUR suggests minimal investment in long-term assets, which may affect future growth potential.
Risk factors include a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting short-term obligations. The dilution potential is low, with no significant changes in shares outstanding between basic and diluted figures.
Recent events and filings do not provide specific details on recent developments, but the consistent negative cash flows and operating losses suggest ongoing financial pressures. The company's financial health is a concern, and it may need to address its liquidity and profitability issues to sustain operations.
- The company has a negative equity position and a high debt-to-equity ratio, indicating significant financial leverage.
- Profitability metrics are poor, with negative returns on assets and operating losses.
- Liquidity is moderate, but the negative net cash position after debt is a concern.
- Growth prospects are unclear due to negative cash flows and minimal capital expenditure.
- The company faces medium liquidity risk and low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- ALTHX.PA Market data — financials · 2026-05-27
- Thx Pharma SA Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Franck MouthonExecutive Chairman of the Board